Acotec Scientific Holdings (HKSE:06669) 3-Year Revenue Growth Rate : 32.90% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Acotec Scientific Holdings 3-Year Revenue Growth Rate?

Acotec Scientific Holdings's Revenue per Share for the six months ended in Dec. 2023 was HK$0.84.

During the past 12 months, Acotec Scientific Holdings's average Revenue per Share Growth Rate was 16.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 32.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 5 years, the highest 3-Year average Revenue per Share Growth Rate of Acotec Scientific Holdings was 49.20% per year. The lowest was 32.90% per year. And the median was 41.05% per year.

Competitive Comparison of Acotec Scientific Holdings's 3-Year Revenue Growth Rate

For the Medical Devices subindustry, Acotec Scientific Holdings's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acotec Scientific Holdings's 3-Year Revenue Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Acotec Scientific Holdings's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Acotec Scientific Holdings's 3-Year Revenue Growth Rate falls into.

Acotec Scientific Holdings 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Acotec Scientific Holdings (HKSE:06669) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Acotec Scientific Holdings 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Acotec Scientific Holdings's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Acotec Scientific Holdings (HKSE:06669) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acotec Scientific Holdings Ltd (HKSE:06669) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

7W3:Germany

Address

16 North Hongda Road, 4-5th Floor, Building No. 1, Beijing Economic-Technological Development Area, Beijing, CHN

Website

http://www.acotec.cn

Acotec Scientific Holdings Ltd is a medical device company. The company is focused on providing leave nothing behind treatment solutions for vascular diseases. It has developed a suite of interventional medical devices featuring world- leading technologies, notably in the fields of drug-coated balloons and thrombus aspiration catheters. The company's commercialized product is Semi-compliant PTCA Balloon (YAN) is a product designed for dilation in coronary artery or coronary artery bypass vessels stenosis to improve myocardial perfusion. Geographically, the company operates from Mainland China, Europe and Other countries and regions. Majority of revenue is generated from Mainland China.

Executives

Vistra Trust (singapore) Pte. Limited	2301 Trustee
Nexus Partners Group Limited	2201 Interest of corporation controlled by you
Cosmic Elite Holdings Limited	2101 Beneficial owner
Li Jing	2201 Interest of corporation controlled by you
Cpechina Fund Iii, L.p.	2201 Interest of corporation controlled by you
Cpe Funds Iii Limited	2201 Interest of corporation controlled by you
Ca Medtech Investment Iii Limited	2201 Interest of corporation controlled by you
Ca Medtech Investment Ii Limited	2201 Interest of corporation controlled by you
Ca Medtech Investment (cayman) Limited	2101 Beneficial owner
Cpe Holdings Limited	2201 Interest of corporation controlled by you
Cpe Holdings International Limited	2201 Interest of corporation controlled by you
Cpe Gof Gp Limited	2201 Interest of corporation controlled by you
Cpe Global Opportunities Fund, L.p.	2201 Interest of corporation controlled by you
Boston Scientific Corporation	2201 Interest of corporation controlled by you
Cpechina Fund Iii, L. P.

Acotec Scientific Holdings (HKSE:06669) Headlines

No Headlines